Today we bring you the final part of our interview with Ron Cohen, founder and CEO of Acorda Therapeutics. We asked him whether there should be greater incentives for investment in biotech companies. We also discussed Acorda’s work on Multiple Sclerosis and the promise it holds for truly changing patients’ lives.